{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:35:38Z","timestamp":1790804138856,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune response to biologics treatment, while widely reported, yet fails to correlate with clinical outcomes and assay to assay comparison is often not possible. Hence, we developed a new peptide based-detection assay to stratify pediatric patients with juvenile idiopathic arthritis (JIA) or chronic non-infectious uveitis (CNU) and monitor anti-drug antibodies (ADAbs) formed as part of an immune response to treatment with the fully human monoclonal therapeutic antibody Adalimumab. Adalimumab derived synthetic peptides were optimized for maximum immunogenicity and were tested by SP-ELISA on a development cohort of 18 JIA and CNU treated patients. The two best performing peptides able to differentiate patient groups were selected for evaluation with a larger scale ELISA testing on a total of 29 sera from pediatric patients with JIA or CNU. The results of this peptide-based assay were compared to an in-house developed SPR biosensor ADAbs assay and a commercially available bridging ELISA. The first peptide, termed HC3, was able to positively detect ADAbs in 7 out of the 29 sera, while the second peptide, called LC3, was able to detect ADAbs in 11 out of 29 sera in the evaluation group. Following statistical data evaluation, it has been found that the detection of ADAbs using the peptide-based ELISA assay positively correlates with disease progression and remission. Two synthetic peptides derived from Adalimumab may provide a beneficial tool to clinicians for monitoring patient response to such treatment and taking informed decisions for treatment alternatives.<\/jats:p>","DOI":"10.1038\/s41598-021-95920-9","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T10:03:40Z","timestamp":1628762620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis"],"prefix":"10.1038","volume":"11","author":[{"given":"Hendrik","family":"Rusche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Marrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feliciana","family":"Real-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Terzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Maccora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Monasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vincenza","family":"Mastrolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Peroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Papini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Rovero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"95920_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry, S., Fautrel, B., Lemelle, I. & Guillemin, F. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. Jt. Bone Spine 81, 112\u2013117 (2014).","journal-title":"Jt. Bone Spine"},{"key":"95920_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrrheum.2009.209","volume":"5","author":"C Macaubas","year":"2009","unstructured":"Macaubas, C., Nguyen, K., Milojevic, D., Park, J. L. & Mellins, E. D. Oligoarticular and polyarticular JIA: Epidemiology and pathogenesis. Nat. Rev. Rheumatol. 5, 616\u2013626 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"95920_CR3","first-page":"1107","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin, T. et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: The SHARE initiative. Ann. Rheum. Dis. 77, 1107\u20131117 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"95920_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand, V. et al. Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. BioDrugs: Clin. Immunother., Biopharm. Gene Ther. 31, 299\u2013316 (2017).","journal-title":"BioDrugs: Clin. Immunother., Biopharm. Gene Ther."},{"key":"95920_CR5","doi-asserted-by":"publisher","first-page":"e12760","DOI":"10.1111\/dth.12760","volume":"32","author":"A Owczarczyk-Saczonek","year":"2019","unstructured":"Owczarczyk-Saczonek, A. et al. Secondary failure of TNF-\u03b1 inhibitors in clinical practice. Dermatol. Therapy 32, e12760 (2019).","journal-title":"Dermatol. Therapy"},{"key":"95920_CR6","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas, S., Demengeot, J. & Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. 72, 1947\u20131955 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"95920_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","volume":"31","author":"T Imagawa","year":"2012","unstructured":"Imagawa, T. et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin. Rheumatol. 31, 1713\u20131721 (2012).","journal-title":"Clin. Rheumatol."},{"key":"95920_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","volume":"72","author":"PA van Schouwenburg","year":"2013","unstructured":"van Schouwenburg, P. A. et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis. 72, 104\u2013109 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"95920_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3109\/00365521.2016.1157894","volume":"51","author":"G Bodini","year":"2016","unstructured":"Bodini, G. et al. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn\u2019s disease. Scand. J. Gastroenterol. 51, 1081\u20131086 (2016).","journal-title":"Scand. J. Gastroenterol."},{"key":"95920_CR10","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1136\/annrheumdis-2014-205554","volume":"73","author":"EH Vogelzang","year":"2014","unstructured":"Vogelzang, E. H. et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; An association with disease activity at 28 and 52 weeks of follow-up. Ann. Rheum. Dis. 73, 2178\u20132182 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"95920_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds, G. M. et al. Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921\u2013926 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"95920_CR12","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","volume":"58","author":"MJH Doeleman","year":"2019","unstructured":"Doeleman, M. J. H., van Maarseveen, E. M. & Swart, J. F. Immunogenicity of biologic agents in juvenile idiopathic arthritis: A systematic review and meta-analysis. Rheumatol. (Oxf.) 58, 1839\u20131849 (2019).","journal-title":"Rheumatol. (Oxf.)"},{"key":"95920_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s10067-018-4057-7","volume":"37","author":"A Marino","year":"2018","unstructured":"Marino, A. et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: Incidence and clinical correlations. Clin. Rheumatol. 37, 1407\u20131411 (2018).","journal-title":"Clin. Rheumatol."},{"key":"95920_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/03009742.2015.1022213","volume":"44","author":"A Skrabl-Baumgartner","year":"2015","unstructured":"Skrabl-Baumgartner, A., Erwa, W., Muntean, W. & Jahnel, J. Anti-adalimumab antibodies in juvenile idiopathic arthritis: Frequent association with loss of response. Scand. J. Rheumatol. 44, 359\u2013362 (2015).","journal-title":"Scand. J. Rheumatol."},{"key":"95920_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10067-019-04798-6","volume":"39","author":"JB Brunelli","year":"2020","unstructured":"Brunelli, J. B. et al. Anti-adalimumab antibodies kinetics: An early guide for juvenile idiopathic arthritis (JIA) switching. Clin. Rheumatol. 39, 515\u2013521 (2020).","journal-title":"Clin. Rheumatol."},{"key":"95920_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner, A., Seidel, G., Langner-Wegscheider, B., Schlagenhauf, A. & Jahnel, J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch. Dis. Child. 104, 246\u2013250 (2019).","journal-title":"Arch. Dis. Child."},{"key":"95920_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell, D. J. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359, 810\u2013820 (2008).","journal-title":"N. Engl. J. Med."},{"key":"95920_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas, R. et al. A Randomized, double-blind, placebo-controlled multicenter study of Adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res. 67, 1503\u20131512 (2015).","journal-title":"Arthritis Care Res."},{"key":"95920_CR19","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.1007\/s00216-015-8915-8","volume":"407","author":"F Real-Fern\u00e1ndez","year":"2015","unstructured":"Real-Fern\u00e1ndez, F. et al. Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. Anal. Bioanal. Chem. 407, 7477\u20137485 (2015).","journal-title":"Anal. Bioanal. Chem."},{"key":"95920_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ab.2018.11.018","volume":"566","author":"F Real-Fern\u00e1ndez","year":"2019","unstructured":"Real-Fern\u00e1ndez, F. et al. Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. Anal. Biochem. 566, 133\u2013138 (2019).","journal-title":"Anal. Biochem."},{"key":"95920_CR21","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.2174\/092986707782360150","volume":"14","author":"K Kessenbrock","year":"2007","unstructured":"Kessenbrock, K., Raijmakers, R., Fritzler, M. J. & Mahler, M. Synthetic peptides: The future of patient management in systemic rheumatic diseases?. Curr. Med. Chem. 14, 2831\u20132838 (2007).","journal-title":"Curr. Med. Chem."},{"key":"95920_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3389\/fimmu.2018.01113","volume":"9","author":"L Martinez-Prat","year":"2018","unstructured":"Martinez-Prat, L. et al. Comparison of serological biomarkers in rheumatoid arthritis and their combination to improve diagnostic performance. Front. Immunol. 9, 1113 (2018).","journal-title":"Front. Immunol."},{"key":"95920_CR23","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.7150\/thno.20654","volume":"7","author":"A Homann","year":"2017","unstructured":"Homann, A. et al. Glycan and peptide IgE epitopes of the TNF-alpha blockers infliximab and Adalimumab\u2014Precision diagnostics by cross-reactivity immune profiling of patient sera. Theranostics 7, 4699\u20134709 (2017).","journal-title":"Theranostics"},{"key":"95920_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/19420862.2018.1518888","volume":"10","author":"N Sekiguchi","year":"2018","unstructured":"Sekiguchi, N. et al. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. MAbs 10, 1168\u20131181 (2018).","journal-title":"MAbs"},{"key":"95920_CR25","doi-asserted-by":"publisher","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","volume":"288","author":"S Hu","year":"2013","unstructured":"Hu, S. et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor \u03b1-associated diseases from a molecular view. J. Biol. Chem. 288, 27059\u201327067 (2013).","journal-title":"J. Biol. Chem."},{"key":"95920_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0076-6879(80)70040-X","volume":"70","author":"EA Kabat","year":"1980","unstructured":"Kabat, E. A. Basic principles of antigen-antibody reaction. Methods Enzymol. 70, 3\u201349 (1980).","journal-title":"Methods Enzymol."},{"key":"95920_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","volume":"74","author":"KA van Schie","year":"2015","unstructured":"van Schie, K. A. et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann. Rheum. Dis. 74, 311\u2013314 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"95920_CR28","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.3389\/fimmu.2019.02921","volume":"10","author":"A Vaisman-Mentesh","year":"2019","unstructured":"Vaisman-Mentesh, A. et al. Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNF\u03b1 antagonists. Front. Immunol. 10, 2921 (2019).","journal-title":"Front. Immunol."},{"key":"95920_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","volume":"11","author":"S Atiqi","year":"2020","unstructured":"Atiqi, S., Hooijberg, F., Loeff, F. C., Rispens, T. & Wolbink, G. J. Immunogenicity of TNF-inhibitors. Front. Immunol. 11, 312 (2020).","journal-title":"Front. Immunol."},{"key":"95920_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","volume":"20","author":"L Aarden","year":"2008","unstructured":"Aarden, L., Ruuls, S. R. & Wolbink, G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 20, 431\u2013435 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"95920_CR31","first-page":"3066","volume":"91","author":"TY Chang","year":"1998","unstructured":"Chang, T. Y. & Siegel, D. L. Genetic and immunological properties of phage-displayed human anti-Rh (D) antibodies: Implications for Rh (D) epitope topology. Blood, J. Am. Soc. Hematol. 91, 3066 (1998).","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"95920_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","volume":"11","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin, S. & Chowers, Y. Tailoring anti-TNF therapy in IBD: Drug levels and disease activity. Nat. Rev. Gastroenterol. Hepatol. 11, 243\u2013255 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"95920_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro, A. et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 61, 658\u2013666 (2009).","journal-title":"Arthritis Rheum."},{"key":"95920_CR34","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/art.34373","volume":"64","author":"A Consolaro","year":"2012","unstructured":"Consolaro, A. et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 64, 2366\u20132374 (2012).","journal-title":"Arthritis Rheum."},{"key":"95920_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs, D. A., Nussenblatt, R. B. & Rosenbaum, J. T. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am. J. Ophthalmol. 140, 509\u2013516 (2005).","journal-title":"Am. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95920-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95920-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95920-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:36:41Z","timestamp":1670071001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95920-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95920"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95920-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16393"}}